DK1948620T3 - Dihydrogenphosphatsalt af en prostaglandin-2D-receptorantagonist - Google Patents

Dihydrogenphosphatsalt af en prostaglandin-2D-receptorantagonist

Info

Publication number: DK1948620T3
Authority: DK; Denmark
Prior art keywords: prostaglandin; receptor antagonist; dihydrogen phosphate; phosphate salt; salt
Prior art date: 2005-10-13

Application number

DK06825836.7T

Other languages

English (en)

Inventor

Beverly Langevin

Edward Orton

Daniel Sherer

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-13

Filing date

2006-10-12

Publication date

2013-06-24

2006-10-12 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2013-06-24 Application granted granted Critical

2013-06-24 Publication of DK1948620T3 publication Critical patent/DK1948620T3/da

Links

NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title 1
150000003180 prostaglandins Chemical class 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK06825836.7T 2005-10-13 2006-10-12 Dihydrogenphosphatsalt af en prostaglandin-2D-receptorantagonist DK1948620T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72629005P	2005-10-13	2005-10-13
PCT/US2006/039901 WO2007047378A2 (en)	2005-10-13	2006-10-12	Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist

Publications (1)

Publication Number	Publication Date
DK1948620T3 true DK1948620T3 (da)	2013-06-24

Family

ID=37963090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06825836.7T DK1948620T3 (da)	2005-10-13	2006-10-12	Dihydrogenphosphatsalt af en prostaglandin-2D-receptorantagonist

Country Status (35)

Country	Link
US (1)	US7642249B2 (da)
EP (1)	EP1948620B1 (da)
JP (1)	JP2009511591A (da)
KR (1)	KR101365480B1 (da)
CN (1)	CN101287714B (da)
AR (1)	AR058085A1 (da)
AU (1)	AU2006304187B2 (da)
BR (1)	BRPI0617311A2 (da)
CA (1)	CA2625563C (da)
CR (1)	CR9870A (da)
DK (1)	DK1948620T3 (da)
DO (2)	DOP2006000223A (da)
EC (1)	ECSP088362A (da)
ES (1)	ES2409833T3 (da)
GT (1)	GT200600457A (da)
HN (1)	HN2008000603A (da)
HR (1)	HRP20130341T1 (da)
IL (1)	IL190673A (da)
MA (1)	MA30005B1 (da)
MY (1)	MY145648A (da)
NI (1)	NI200800116A (da)
NO (1)	NO20082072L (da)
NZ (1)	NZ567433A (da)
PE (1)	PE20070791A1 (da)
PL (1)	PL1948620T3 (da)
PT (1)	PT1948620E (da)
RS (1)	RS52799B (da)
RU (1)	RU2419614C2 (da)
SI (1)	SI1948620T1 (da)
TN (1)	TNSN08131A1 (da)
TW (1)	TW200728288A (da)
UA (1)	UA93062C2 (da)
UY (1)	UY29862A1 (da)
WO (1)	WO2007047378A2 (da)
ZA (1)	ZA200802586B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
AR060403A1 (es) *	2006-04-12	2008-06-11	Sanofi Aventis	Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
WO2007146838A2 (en) *	2006-06-09	2007-12-21	Icos Corporation	Substituted phenyl acetic acids as dp-2 antagonists
WO2009006086A2 (en) *	2007-06-29	2009-01-08	Sanofi-Aventis	A new process for preparing 2-(3-{6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxypyrimidin-4-yl}-phenyl)- 2-methylpropionic acid
CA2713139C (en)	2008-02-01	2013-04-23	Amira Pharmaceuticals, Inc.	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EP2245022A4 (en) *	2008-02-25	2012-02-22	Panmira Pharmaceuticals Llc	ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en)	2008-10-01	2010-04-08	Amira Pharmaceuticals, Inc.	Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en)	2008-10-08	2010-04-15	Amira Pharmaceuticals, Inc.	Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
US20100112606A1 (en) *	2008-10-17	2010-05-06	Michael Armstrong	Measurement and analysis of leukotrienes
AR074776A1 (es) *	2008-12-18	2011-02-09	Sanofi Aventis	Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2011014587A2 (en)	2009-07-31	2011-02-03	Amira Pharmaceuticals, Inc.	Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
CN102596902A (zh)	2009-08-05	2012-07-18	潘米拉制药公司	Dp2拮抗剂及其用途
EP2590640A1 (en)	2010-07-08	2013-05-15	Ramot at Tel-Aviv University Ltd	Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
WO2012044561A2 (en) *	2010-09-30	2012-04-05	Merck Sharp & Dohme Corp.	2-alkoxy pyrimidine pde10 inhibitors
WO2014066568A1 (en)	2012-10-24	2014-05-01	Winthrop-University Hospital	Non-invasive biomarker to identify subjects at risk of preterm delivery
WO2016128565A1 (en)	2015-02-13	2016-08-18	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
WO2016193939A1 (en)	2015-06-04	2016-12-08	Aurigene Discovery Technologies Limited	Substituted heterocyclyl derivatives as cdk inhibitors
US20200264188A1 (en)	2017-09-13	2020-08-20	Progenity, Inc.	Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en)	2019-12-04	2023-12-20	Biora Therapeutics, Inc.	ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4711888A (en) *	1985-07-24	1987-12-08	Pfizer Inc.	Hydroxy and alkoxy pyrimidines
CA2469316A1 (en) *	2001-12-07	2003-06-19	Vertex Pharmaceuticals, Inc.	Pyrimidine-based compounds useful as gsk-3 inhibitors
MXPA06000269A (es) *	2003-07-09	2006-04-07	Hoffmann La Roche	Tiofenilaminoimidazolinas.
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2

2006
- 2006-10-11 GT GT200600457A patent/GT200600457A/es unknown
- 2006-10-12 RS RS20130225A patent/RS52799B/sr unknown
- 2006-10-12 PL PL06825836T patent/PL1948620T3/pl unknown
- 2006-10-12 HR HRP20130341TT patent/HRP20130341T1/hr unknown
- 2006-10-12 MY MYPI20081085A patent/MY145648A/en unknown
- 2006-10-12 UA UAA200806196A patent/UA93062C2/ru unknown
- 2006-10-12 EP EP06825836A patent/EP1948620B1/en active Active
- 2006-10-12 JP JP2008535672A patent/JP2009511591A/ja not_active Abandoned
- 2006-10-12 BR BRPI0617311-0A patent/BRPI0617311A2/pt not_active IP Right Cessation
- 2006-10-12 PT PT68258367T patent/PT1948620E/pt unknown
- 2006-10-12 DK DK06825836.7T patent/DK1948620T3/da active
- 2006-10-12 AR ARP060104475A patent/AR058085A1/es not_active Application Discontinuation
- 2006-10-12 AU AU2006304187A patent/AU2006304187B2/en not_active Ceased
- 2006-10-12 CN CN2006800378860A patent/CN101287714B/zh not_active Expired - Fee Related
- 2006-10-12 KR KR1020087008805A patent/KR101365480B1/ko not_active Expired - Fee Related
- 2006-10-12 WO PCT/US2006/039901 patent/WO2007047378A2/en not_active Ceased
- 2006-10-12 PE PE2006001242A patent/PE20070791A1/es not_active Application Discontinuation
- 2006-10-12 CA CA2625563A patent/CA2625563C/en not_active Expired - Fee Related
- 2006-10-12 SI SI200631572T patent/SI1948620T1/sl unknown
- 2006-10-12 NZ NZ567433A patent/NZ567433A/en not_active IP Right Cessation
- 2006-10-12 ES ES06825836T patent/ES2409833T3/es active Active
- 2006-10-12 RU RU2008118491/04A patent/RU2419614C2/ru not_active IP Right Cessation
- 2006-10-13 TW TW095137635A patent/TW200728288A/zh unknown
- 2006-10-13 DO DO2006P000223A patent/DOP2006000223A/es unknown
- 2006-10-13 UY UY29862A patent/UY29862A1/es unknown
- 2006-10-13 DO DO2006000220A patent/DOP2006000220A/es unknown
2008
- 2008-03-19 TN TNP2008000131A patent/TNSN08131A1/en unknown
- 2008-03-20 ZA ZA200802586A patent/ZA200802586B/xx unknown
- 2008-04-07 IL IL190673A patent/IL190673A/en not_active IP Right Cessation
- 2008-04-07 CR CR9870A patent/CR9870A/es not_active Application Discontinuation
- 2008-04-10 EC EC2008008362A patent/ECSP088362A/es unknown
- 2008-04-11 NI NI200800116A patent/NI200800116A/es unknown
- 2008-04-11 US US12/101,282 patent/US7642249B2/en not_active Expired - Fee Related
- 2008-04-11 HN HN2008000603A patent/HN2008000603A/es unknown
- 2008-05-02 NO NO20082072A patent/NO20082072L/no not_active Application Discontinuation
- 2008-05-02 MA MA30890A patent/MA30005B1/fr unknown

Also Published As

Publication number	Publication date
EP1948620B1 (en)	2013-03-20
CA2625563C (en)	2011-04-19
US7642249B2 (en)	2010-01-05
MY145648A (en)	2012-03-15
SI1948620T1 (sl)	2013-05-31
DOP2006000220A (es)	2007-05-15
MA30005B1 (fr)	2008-12-01
CN101287714B (zh)	2011-04-06
TW200728288A (en)	2007-08-01
HRP20130341T1 (en)	2013-05-31
KR20080057275A (ko)	2008-06-24
UA93062C2 (ru)	2011-01-10
TNSN08131A1 (en)	2009-07-14
BRPI0617311A2 (pt)	2011-07-19
PE20070791A1 (es)	2007-08-16
ES2409833T3 (es)	2013-06-28
CR9870A (es)	2008-06-18
US20080194600A1 (en)	2008-08-14
PT1948620E (pt)	2013-05-06
CN101287714A (zh)	2008-10-15
IL190673A0 (en)	2008-11-03
HN2008000603A (es)	2010-11-03
PL1948620T3 (pl)	2013-08-30
UY29862A1 (es)	2007-05-31
RU2008118491A (ru)	2009-11-20
AU2006304187B2 (en)	2011-04-28
WO2007047378A3 (en)	2007-08-02
HK1125133A1 (en)	2009-07-31
CA2625563A1 (en)	2007-04-26
AR058085A1 (es)	2008-01-23
AU2006304187A1 (en)	2007-04-26
WO2007047378A2 (en)	2007-04-26
ZA200802586B (en)	2009-09-30
EP1948620A2 (en)	2008-07-30
RU2419614C2 (ru)	2011-05-27
JP2009511591A (ja)	2009-03-19
KR101365480B1 (ko)	2014-02-21
DOP2006000223A (es)	2007-05-15
NZ567433A (en)	2010-06-25
NI200800116A (es)	2011-12-15
NO20082072L (no)	2008-05-02
ECSP088362A (es)	2008-05-30
GT200600457A (es)	2007-04-27
IL190673A (en)	2011-12-29
RS52799B (sr)	2013-10-31
ES2409833T8 (es)	2013-09-26

Publication	Publication Date	Title
CR9870A (es)	2008-06-18	Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist
FIC20230039I1 (fi)	2023-12-22	Sedatsuridiini tai tämän farmaseuttisesti hyväksyttävä suola
FR22C1030I1 (fr)	2022-09-09	Formes cristallines d'un inhibiteur de la prolyle hydroxylase
FIC20240046I1 (fi)	2024-12-16	Vibegroni tai sen farmaseuttisesti hyväksyttävä suola
NO2022057I1 (no)	2022-12-13	Capmatinib or a pharmaceutically acceptable salt thereof
FIC20240041I1 (fi)	2024-12-02	Aprositentaani tai sen farmaseuttisesti hyväksyttävä suola
BRPI0913930A2 (pt)	2015-10-20	antagonistas de receptores de prostaglandinas d2
DK2152879T3 (da)	2013-02-18	RNA antagonistforbindelser til modulering af beta-catenin
EP2854859A4 (en)	2016-01-13	CRYSTALLINE FORMS OF A BRUTON TYROSINE KINASE HEATHER
DK1962817T3 (da)	2011-03-07	Transdermal tilførsel af et salt af meptazinol
DK2066628T3 (da)	2011-02-07	2-Phenylindoler som antagonister af prostaglandin-D2-receptorer
BRPI0811156A2 (pt)	2019-09-24	compostos antagonistas de rna para a modulação de her3
FR2939815B1 (fr)	2012-03-09	Bloc a bancher pour la construction de mur
DK2021486T4 (da)	2022-03-07	System til fremstilling af bioorganiske forbindelser
BRPI1008829A2 (pt)	2016-03-15	forma cristalina de dihidrogenofosfato de (r)-3-(4-(2-(2-metiltetrazol-5-il) piridin-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona
BRPI0714764A2 (pt)	2014-12-30	Derivados substituídos de sulfonamida
BRPI0810926A2 (pt)	2014-11-04	Antagonista de crig
DK1856050T3 (da)	2010-02-01	Krystallinske former af en biphenylforbindelse
BRPI0819902A2 (pt)	2015-05-19	C2-c5-alquil-imidazol-bifosfonatos
PT2146944E (pt)	2014-03-11	Processo para a preparação de folatos marcados com 18f
DK2307435T3 (da)	2012-09-10	Salte af HIV-inhibitorforbindelser
BRPI0914531A2 (pt)	2015-08-04	"método para a preparação de um polimorfo a"
ITPR20070098A1 (it)	2009-06-22	Procedimento per idratare un terreno coesivo mediante elettrosmosi perimpedirne la riduzione volumetrica per disidratazione
PL1723157T3 (pl)	2008-04-30	Amorficzne postaci rizedronianu monosodowego
ITMI20051989A1 (it)	2007-04-21	Procedimerntyo per la preparazione di composti antagonisti di angiotensina ii